nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—thyroid cancer—lung cancer	0.123	0.398	CtDrD
Sorafenib—liver cancer—lung cancer	0.118	0.384	CtDrD
Sorafenib—kidney cancer—lung cancer	0.0671	0.218	CtDrD
Sorafenib—RAF1—lung cancer	0.0411	0.174	CbGaD
Sorafenib—FGFR1—lung cancer	0.0405	0.171	CbGaD
Sorafenib—FLT1—lung cancer	0.0387	0.164	CbGaD
Sorafenib—BRAF—lung cancer	0.0285	0.121	CbGaD
Sorafenib—KDR—lung cancer	0.0243	0.103	CbGaD
Sorafenib—KIT—lung cancer	0.0229	0.0968	CbGaD
Sorafenib—UGT1A1—lung cancer	0.0225	0.0953	CbGaD
Sorafenib—MKNK2—Gefitinib—lung cancer	0.0217	0.0723	CbGbCtD
Sorafenib—CDK7—Crizotinib—lung cancer	0.0184	0.0613	CbGbCtD
Sorafenib—MUSK—Crizotinib—lung cancer	0.0184	0.0613	CbGbCtD
Sorafenib—MKNK1—Gefitinib—lung cancer	0.0172	0.0575	CbGbCtD
Sorafenib—TIE1—Crizotinib—lung cancer	0.0133	0.0443	CbGbCtD
Sorafenib—TAOK2—Crizotinib—lung cancer	0.0133	0.0443	CbGbCtD
Sorafenib—ABCG2—lung cancer	0.0127	0.0536	CbGaD
Sorafenib—HIPK4—Gefitinib—lung cancer	0.011	0.0367	CbGbCtD
Sorafenib—EPHA6—Gefitinib—lung cancer	0.011	0.0367	CbGbCtD
Sorafenib—MKNK1—Erlotinib—lung cancer	0.0102	0.034	CbGbCtD
Sorafenib—AURKC—Erlotinib—lung cancer	0.0102	0.034	CbGbCtD
Sorafenib—STK10—Gefitinib—lung cancer	0.00988	0.033	CbGbCtD
Sorafenib—MAP2K5—Gefitinib—lung cancer	0.00899	0.03	CbGbCtD
Sorafenib—MAP3K19—Gefitinib—lung cancer	0.00826	0.0276	CbGbCtD
Sorafenib—FLT3—Crizotinib—lung cancer	0.00762	0.0255	CbGbCtD
Sorafenib—FLT3—Erlotinib—lung cancer	0.00735	0.0246	CbGbCtD
Sorafenib—EPHB6—Crizotinib—lung cancer	0.00674	0.0225	CbGbCtD
Sorafenib—EPHA6—Crizotinib—lung cancer	0.00674	0.0225	CbGbCtD
Sorafenib—EPHA6—Erlotinib—lung cancer	0.0065	0.0217	CbGbCtD
Sorafenib—HIPK4—Erlotinib—lung cancer	0.0065	0.0217	CbGbCtD
Sorafenib—STK10—Crizotinib—lung cancer	0.00605	0.0202	CbGbCtD
Sorafenib—CSF1R—Crizotinib—lung cancer	0.00605	0.0202	CbGbCtD
Sorafenib—STK10—Erlotinib—lung cancer	0.00584	0.0195	CbGbCtD
Sorafenib—MAP2K5—Erlotinib—lung cancer	0.00532	0.0178	CbGbCtD
Sorafenib—ABCB1—lung cancer	0.00527	0.0223	CbGaD
Sorafenib—MAP3K19—Crizotinib—lung cancer	0.00506	0.0169	CbGbCtD
Sorafenib—RALBP1—Doxorubicin—lung cancer	0.00502	0.0168	CbGbCtD
Sorafenib—MAP3K19—Erlotinib—lung cancer	0.00489	0.0163	CbGbCtD
Sorafenib—UGT1A9—Irinotecan—lung cancer	0.00194	0.00647	CbGbCtD
Sorafenib—ABCG2—Topotecan—lung cancer	0.00178	0.00596	CbGbCtD
Sorafenib—UGT1A1—Erlotinib—lung cancer	0.00175	0.00586	CbGbCtD
Sorafenib—ABCG2—Gefitinib—lung cancer	0.00163	0.00545	CbGbCtD
Sorafenib—UGT1A1—Irinotecan—lung cancer	0.00158	0.00529	CbGbCtD
Sorafenib—ABCG2—Teniposide—lung cancer	0.00158	0.00528	CbGbCtD
Sorafenib—UGT1A1—Etoposide—lung cancer	0.00127	0.00424	CbGbCtD
Sorafenib—ABCC2—Paclitaxel—lung cancer	0.000977	0.00326	CbGbCtD
Sorafenib—ABCG2—Erlotinib—lung cancer	0.000964	0.00322	CbGbCtD
Sorafenib—ABCC2—Irinotecan—lung cancer	0.000963	0.00322	CbGbCtD
Sorafenib—CYP3A5—Gefitinib—lung cancer	0.000904	0.00302	CbGbCtD
Sorafenib—ABCG2—Paclitaxel—lung cancer	0.000883	0.00295	CbGbCtD
Sorafenib—CYP3A5—Teniposide—lung cancer	0.000876	0.00293	CbGbCtD
Sorafenib—ABCG2—Irinotecan—lung cancer	0.000871	0.00291	CbGbCtD
Sorafenib—ABCC4—Methotrexate—lung cancer	0.000857	0.00286	CbGbCtD
Sorafenib—ABCC2—Vinblastine—lung cancer	0.000857	0.00286	CbGbCtD
Sorafenib—ABCC2—Cisplatin—lung cancer	0.000785	0.00262	CbGbCtD
Sorafenib—FLT1—umbilical vein—lung cancer	0.000784	0.0279	CbGeAlD
Sorafenib—ABCC2—Etoposide—lung cancer	0.000772	0.00258	CbGbCtD
Sorafenib—CYP2C19—Gefitinib—lung cancer	0.000729	0.00244	CbGbCtD
Sorafenib—ABCG2—Cisplatin—lung cancer	0.00071	0.00237	CbGbCtD
Sorafenib—CYP2C19—Teniposide—lung cancer	0.000707	0.00236	CbGbCtD
Sorafenib—ABCC2—Docetaxel—lung cancer	0.000706	0.00236	CbGbCtD
Sorafenib—ABCG2—Etoposide—lung cancer	0.000698	0.00233	CbGbCtD
Sorafenib—KDR—umbilical vein—lung cancer	0.000663	0.0236	CbGeAlD
Sorafenib—CYP3A7—Paclitaxel—lung cancer	0.000652	0.00218	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Paclitaxel—lung cancer	0.000652	0.00218	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Irinotecan—lung cancer	0.000643	0.00215	CbGbCtD
Sorafenib—CYP3A7—Irinotecan—lung cancer	0.000643	0.00215	CbGbCtD
Sorafenib—ABCB1—Topotecan—lung cancer	0.000643	0.00215	CbGbCtD
Sorafenib—ABCG2—Docetaxel—lung cancer	0.000638	0.00213	CbGbCtD
Sorafenib—CYP2B6—Irinotecan—lung cancer	0.000613	0.00205	CbGbCtD
Sorafenib—CYP2C9—Gefitinib—lung cancer	0.000606	0.00202	CbGbCtD
Sorafenib—MAPK11—mammary gland—lung cancer	0.0006	0.0213	CbGeAlD
Sorafenib—CDK7—mammary gland—lung cancer	0.00059	0.021	CbGeAlD
Sorafenib—ABCB1—Gefitinib—lung cancer	0.000588	0.00196	CbGbCtD
Sorafenib—CYP2C9—Teniposide—lung cancer	0.000588	0.00196	CbGbCtD
Sorafenib—MAPK15—bronchus—lung cancer	0.000555	0.0197	CbGeAlD
Sorafenib—CYP2D6—Gefitinib—lung cancer	0.000554	0.00185	CbGbCtD
Sorafenib—CYP3A5—Crizotinib—lung cancer	0.000554	0.00185	CbGbCtD
Sorafenib—CYP3A5—Erlotinib—lung cancer	0.000534	0.00178	CbGbCtD
Sorafenib—ABCC2—Doxorubicin—lung cancer	0.000526	0.00176	CbGbCtD
Sorafenib—CYP2C8—Erlotinib—lung cancer	0.000514	0.00172	CbGbCtD
Sorafenib—ABCC2—Methotrexate—lung cancer	0.00051	0.0017	CbGbCtD
Sorafenib—ZAK—mammary gland—lung cancer	0.00051	0.0181	CbGeAlD
Sorafenib—CYP2B6—Cisplatin—lung cancer	0.000499	0.00167	CbGbCtD
Sorafenib—HIPK3—mammary gland—lung cancer	0.000499	0.0178	CbGeAlD
Sorafenib—CYP3A5—Paclitaxel—lung cancer	0.000489	0.00163	CbGbCtD
Sorafenib—CYP3A5—Irinotecan—lung cancer	0.000483	0.00161	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—lung cancer	0.000476	0.00159	CbGbCtD
Sorafenib—CYP3A7—Docetaxel—lung cancer	0.000471	0.00157	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Docetaxel—lung cancer	0.000471	0.00157	CbGbCtD
Sorafenib—CYP2C8—Paclitaxel—lung cancer	0.00047	0.00157	CbGbCtD
Sorafenib—RAF1—Topotecan—Irinotecan—lung cancer	0.000463	0.444	CbGdCrCtD
Sorafenib—ABCG2—Methotrexate—lung cancer	0.000461	0.00154	CbGbCtD
Sorafenib—ABCB1—Vinorelbine—lung cancer	0.000453	0.00151	CbGbCtD
Sorafenib—EPHX2—mammary gland—lung cancer	0.000427	0.0152	CbGeAlD
Sorafenib—CYP2D6—Vinorelbine—lung cancer	0.000427	0.00143	CbGbCtD
Sorafenib—CYP1A2—Erlotinib—lung cancer	0.000398	0.00133	CbGbCtD
Sorafenib—CDK7—respiratory system—lung cancer	0.000393	0.014	CbGeAlD
Sorafenib—CYP3A5—Etoposide—lung cancer	0.000387	0.00129	CbGbCtD
Sorafenib—CYP3A4—Topotecan—lung cancer	0.000385	0.00129	CbGbCtD
Sorafenib—CYP2C8—Etoposide—lung cancer	0.000372	0.00124	CbGbCtD
Sorafenib—Regorafenib—RAF1—lung cancer	0.000363	0.161	CrCbGaD
Sorafenib—ABCB1—Crizotinib—lung cancer	0.000361	0.0012	CbGbCtD
Sorafenib—MAP3K7—mammary gland—lung cancer	0.00036	0.0128	CbGeAlD
Sorafenib—Regorafenib—FGFR1—lung cancer	0.000357	0.159	CrCbGaD
Sorafenib—CYP3A5—Docetaxel—lung cancer	0.000354	0.00118	CbGbCtD
Sorafenib—CYP3A4—Gefitinib—lung cancer	0.000352	0.00118	CbGbCtD
Sorafenib—ABCB1—Gemcitabine—lung cancer	0.000352	0.00118	CbGbCtD
Sorafenib—CDK7—Topotecan—Irinotecan—lung cancer	0.000351	0.336	CbGdCrCtD
Sorafenib—MKNK2—mammary gland—lung cancer	0.000349	0.0124	CbGeAlD
Sorafenib—ABCB1—Erlotinib—lung cancer	0.000348	0.00116	CbGbCtD
Sorafenib—MKNK1—mammary gland—lung cancer	0.000344	0.0123	CbGeAlD
Sorafenib—CYP3A4—Teniposide—lung cancer	0.000342	0.00114	CbGbCtD
Sorafenib—Regorafenib—FLT1—lung cancer	0.000341	0.152	CrCbGaD
Sorafenib—RET—mammary gland—lung cancer	0.00034	0.0121	CbGeAlD
Sorafenib—ZAK—respiratory system—lung cancer	0.00034	0.0121	CbGeAlD
Sorafenib—CYP2B6—Doxorubicin—lung cancer	0.000335	0.00112	CbGbCtD
Sorafenib—CYP2C9—Paclitaxel—lung cancer	0.000328	0.0011	CbGbCtD
Sorafenib—CYP2D6—Erlotinib—lung cancer	0.000328	0.00109	CbGbCtD
Sorafenib—MAP3K19—respiratory system—lung cancer	0.000326	0.0116	CbGeAlD
Sorafenib—ABCB1—Paclitaxel—lung cancer	0.000318	0.00106	CbGbCtD
Sorafenib—ABCB1—Irinotecan—lung cancer	0.000314	0.00105	CbGbCtD
Sorafenib—TIE1—respiratory system—lung cancer	0.000311	0.0111	CbGeAlD
Sorafenib—CYP1A2—Etoposide—lung cancer	0.000288	0.000961	CbGbCtD
Sorafenib—FLT3—respiratory system—lung cancer	0.000283	0.0101	CbGeAlD
Sorafenib—PDGFRA—mammary gland—lung cancer	0.000281	0.00999	CbGeAlD
Sorafenib—ZAK—bronchus—lung cancer	0.00028	0.00995	CbGeAlD
Sorafenib—ABCB1—Vinblastine—lung cancer	0.000279	0.000933	CbGbCtD
Sorafenib—HIPK3—bronchus—lung cancer	0.000274	0.00974	CbGeAlD
Sorafenib—CYP3A4—Vinorelbine—lung cancer	0.000271	0.000907	CbGbCtD
Sorafenib—CYP2C9—Cisplatin—lung cancer	0.000264	0.000881	CbGbCtD
Sorafenib—CYP2D6—Vinblastine—lung cancer	0.000263	0.000879	CbGbCtD
Sorafenib—TIE1—epithelium—lung cancer	0.00026	0.00924	CbGeAlD
Sorafenib—FLT4—respiratory system—lung cancer	0.000257	0.00914	CbGeAlD
Sorafenib—ABCB1—Cisplatin—lung cancer	0.000256	0.000855	CbGbCtD
Sorafenib—KDR—mammary gland—lung cancer	0.000253	0.00901	CbGeAlD
Sorafenib—ABCB1—Etoposide—lung cancer	0.000252	0.00084	CbGbCtD
Sorafenib—Regorafenib—BRAF—lung cancer	0.000252	0.112	CrCbGaD
Sorafenib—CSF1R—mammary gland—lung cancer	0.000247	0.0088	CbGeAlD
Sorafenib—MKNK2—respiratory system—lung cancer	0.000232	0.00827	CbGeAlD
Sorafenib—HIPK3—cardiac atrium—lung cancer	0.000231	0.00821	CbGeAlD
Sorafenib—ABCB1—Docetaxel—lung cancer	0.00023	0.000769	CbGbCtD
Sorafenib—KIT—mammary gland—lung cancer	0.000224	0.00799	CbGeAlD
Sorafenib—PDGFRB—mammary gland—lung cancer	0.000219	0.0078	CbGeAlD
Sorafenib—CYP3A4—Crizotinib—lung cancer	0.000216	0.000722	CbGbCtD
Sorafenib—TIE1—cardiac atrium—lung cancer	0.000216	0.00768	CbGeAlD
Sorafenib—FLT4—epithelium—lung cancer	0.000215	0.00764	CbGeAlD
Sorafenib—Regorafenib—KDR—lung cancer	0.000214	0.0951	CrCbGaD
Sorafenib—RALBP1—respiratory system—lung cancer	0.00021	0.00747	CbGeAlD
Sorafenib—CDK7—lung—lung cancer	0.000209	0.00743	CbGeAlD
Sorafenib—FGFR1—bronchus—lung cancer	0.000208	0.00742	CbGeAlD
Sorafenib—CYP3A4—Erlotinib—lung cancer	0.000208	0.000696	CbGbCtD
Sorafenib—TAOK2—lung—lung cancer	0.000207	0.00737	CbGeAlD
Sorafenib—Regorafenib—KIT—lung cancer	0.000202	0.0897	CrCbGaD
Sorafenib—FLT1—respiratory system—lung cancer	0.0002	0.00711	CbGeAlD
Sorafenib—Regorafenib—UGT1A1—lung cancer	0.000199	0.0884	CrCbGaD
Sorafenib—RAF1—respiratory system—lung cancer	0.000198	0.00706	CbGeAlD
Sorafenib—MAP3K7—bronchus—lung cancer	0.000197	0.00702	CbGeAlD
Sorafenib—HIPK3—bone marrow—lung cancer	0.000195	0.00694	CbGeAlD
Sorafenib—MKNK2—epithelium—lung cancer	0.000194	0.00691	CbGeAlD
Sorafenib—MKNK2—bronchus—lung cancer	0.000191	0.00681	CbGeAlD
Sorafenib—CYP3A4—Paclitaxel—lung cancer	0.000191	0.000637	CbGbCtD
Sorafenib—RET—epithelium—lung cancer	0.000189	0.00674	CbGeAlD
Sorafenib—STK10—respiratory system—lung cancer	0.000189	0.00673	CbGeAlD
Sorafenib—MKNK1—bronchus—lung cancer	0.000189	0.00672	CbGeAlD
Sorafenib—CYP3A4—Irinotecan—lung cancer	0.000188	0.000629	CbGbCtD
Sorafenib—PDGFRA—respiratory system—lung cancer	0.000187	0.00666	CbGeAlD
Sorafenib—ZAK—lung—lung cancer	0.00018	0.00642	CbGeAlD
Sorafenib—MAP3K7—trachea—lung cancer	0.000177	0.00631	CbGeAlD
Sorafenib—HIPK3—lung—lung cancer	0.000177	0.00628	CbGeAlD
Sorafenib—FGFR1—cardiac atrium—lung cancer	0.000176	0.00626	CbGeAlD
Sorafenib—BRAF—bone marrow—lung cancer	0.000175	0.00621	CbGeAlD
Sorafenib—MAP3K19—lung—lung cancer	0.000173	0.00616	CbGeAlD
Sorafenib—RALBP1—bronchus—lung cancer	0.000173	0.00615	CbGeAlD
Sorafenib—MKNK2—trachea—lung cancer	0.000172	0.00611	CbGeAlD
Sorafenib—ABCB1—Doxorubicin—lung cancer	0.000172	0.000573	CbGbCtD
Sorafenib—KDR—respiratory system—lung cancer	0.000169	0.00601	CbGeAlD
Sorafenib—CYP3A4—Vinblastine—lung cancer	0.000167	0.000559	CbGbCtD
Sorafenib—FLT1—epithelium—lung cancer	0.000167	0.00594	CbGeAlD
Sorafenib—MAP3K7—cardiac atrium—lung cancer	0.000166	0.00593	CbGeAlD
Sorafenib—ABCB1—Methotrexate—lung cancer	0.000166	0.000555	CbGbCtD
Sorafenib—RAF1—epithelium—lung cancer	0.000166	0.0059	CbGeAlD
Sorafenib—FLT3—bone marrow—lung cancer	0.000166	0.0059	CbGeAlD
Sorafenib—TIE1—lung—lung cancer	0.000165	0.00587	CbGeAlD
Sorafenib—CSF1R—respiratory system—lung cancer	0.000165	0.00586	CbGeAlD
Sorafenib—FLT1—bronchus—lung cancer	0.000164	0.00585	CbGeAlD
Sorafenib—RAF1—bronchus—lung cancer	0.000163	0.00581	CbGeAlD
Sorafenib—EPHB6—bronchus—lung cancer	0.000162	0.00578	CbGeAlD
Sorafenib—CYP2D6—Doxorubicin—lung cancer	0.000162	0.00054	CbGbCtD
Sorafenib—MKNK2—cardiac atrium—lung cancer	0.000161	0.00574	CbGeAlD
Sorafenib—MKNK1—cardiac atrium—lung cancer	0.000159	0.00567	CbGeAlD
Sorafenib—BRAF—lung—lung cancer	0.000158	0.00563	CbGeAlD
Sorafenib—STK10—bronchus—lung cancer	0.000156	0.00554	CbGeAlD
Sorafenib—RALBP1—trachea—lung cancer	0.000155	0.00552	CbGeAlD
Sorafenib—EPHX2—lung—lung cancer	0.000151	0.00538	CbGeAlD
Sorafenib—CYP3A4—Etoposide—lung cancer	0.000151	0.000503	CbGbCtD
Sorafenib—FLT4—bone marrow—lung cancer	0.00015	0.00536	CbGeAlD
Sorafenib—FLT3—lung—lung cancer	0.00015	0.00534	CbGeAlD
Sorafenib—KIT—respiratory system—lung cancer	0.00015	0.00532	CbGeAlD
Sorafenib—FLT1—trachea—lung cancer	0.000148	0.00525	CbGeAlD
Sorafenib—RAF1—trachea—lung cancer	0.000147	0.00522	CbGeAlD
Sorafenib—PDGFRB—respiratory system—lung cancer	0.000146	0.0052	CbGeAlD
Sorafenib—EPHB6—trachea—lung cancer	0.000146	0.00519	CbGeAlD
Sorafenib—RALBP1—cardiac atrium—lung cancer	0.000146	0.00519	CbGeAlD
Sorafenib—MAPK11—lymph node—lung cancer	0.000145	0.00516	CbGeAlD
Sorafenib—CDK7—lymph node—lung cancer	0.000143	0.00508	CbGeAlD
Sorafenib—TAOK2—lymph node—lung cancer	0.000142	0.00504	CbGeAlD
Sorafenib—KDR—epithelium—lung cancer	0.000141	0.00502	CbGeAlD
Sorafenib—MAP3K7—bone marrow—lung cancer	0.000141	0.005	CbGeAlD
Sorafenib—AURKC—lymph node—lung cancer	0.000141	0.005	CbGeAlD
Sorafenib—KDR—bronchus—lung cancer	0.000139	0.00494	CbGeAlD
Sorafenib—MAP2K5—bronchus—lung cancer	0.000139	0.00494	CbGeAlD
Sorafenib—FLT1—cardiac atrium—lung cancer	0.000139	0.00493	CbGeAlD
Sorafenib—PDGFRA—trachea—lung cancer	0.000138	0.00492	CbGeAlD
Sorafenib—CYP3A4—Docetaxel—lung cancer	0.000138	0.000461	CbGbCtD
Sorafenib—RAF1—cardiac atrium—lung cancer	0.000138	0.0049	CbGeAlD
Sorafenib—EPHB6—cardiac atrium—lung cancer	0.000137	0.00488	CbGeAlD
Sorafenib—FLT4—lung—lung cancer	0.000136	0.00485	CbGeAlD
Sorafenib—MKNK2—bone marrow—lung cancer	0.000136	0.00485	CbGeAlD
Sorafenib—CSF1R—bronchus—lung cancer	0.000136	0.00482	CbGeAlD
Sorafenib—FGFR1—lung—lung cancer	0.000135	0.00479	CbGeAlD
Sorafenib—MKNK1—bone marrow—lung cancer	0.000135	0.00479	CbGeAlD
Sorafenib—MAP3K7—lung—lung cancer	0.000127	0.00453	CbGeAlD
Sorafenib—CYP2C8—mammary gland—lung cancer	0.000127	0.00451	CbGeAlD
Sorafenib—KIT—epithelium—lung cancer	0.000125	0.00445	CbGeAlD
Sorafenib—KDR—trachea—lung cancer	0.000125	0.00444	CbGeAlD
Sorafenib—MAP2K5—trachea—lung cancer	0.000125	0.00444	CbGeAlD
Sorafenib—MKNK2—lung—lung cancer	0.000123	0.00439	CbGeAlD
Sorafenib—ZAK—lymph node—lung cancer	0.000123	0.00439	CbGeAlD
Sorafenib—KIT—bronchus—lung cancer	0.000123	0.00438	CbGeAlD
Sorafenib—RALBP1—bone marrow—lung cancer	0.000123	0.00438	CbGeAlD
Sorafenib—PDGFRB—epithelium—lung cancer	0.000122	0.00434	CbGeAlD
Sorafenib—MKNK1—lung—lung cancer	0.000122	0.00434	CbGeAlD
Sorafenib—CSF1R—trachea—lung cancer	0.000122	0.00433	CbGeAlD
Sorafenib—HIPK3—lymph node—lung cancer	0.000121	0.0043	CbGeAlD
Sorafenib—PDGFRB—bronchus—lung cancer	0.00012	0.00428	CbGeAlD
Sorafenib—KDR—cardiac atrium—lung cancer	0.000117	0.00417	CbGeAlD
Sorafenib—MAP2K5—cardiac atrium—lung cancer	0.000117	0.00417	CbGeAlD
Sorafenib—RAF1—bone marrow—lung cancer	0.000116	0.00414	CbGeAlD
Sorafenib—CSF1R—cardiac atrium—lung cancer	0.000114	0.00407	CbGeAlD
Sorafenib—TIE1—lymph node—lung cancer	0.000113	0.00402	CbGeAlD
Sorafenib—CYP2C9—mammary gland—lung cancer	0.000113	0.00401	CbGeAlD
Sorafenib—Regorafenib—ABCG2—lung cancer	0.000112	0.0497	CrCbGaD
Sorafenib—RALBP1—lung—lung cancer	0.000111	0.00397	CbGeAlD
Sorafenib—STK10—bone marrow—lung cancer	0.000111	0.00394	CbGeAlD
Sorafenib—KIT—trachea—lung cancer	0.000111	0.00393	CbGeAlD
Sorafenib—BRAF—lymph node—lung cancer	0.000108	0.00385	CbGeAlD
Sorafenib—PDGFRB—trachea—lung cancer	0.000108	0.00384	CbGeAlD
Sorafenib—FLT1—lung—lung cancer	0.000106	0.00377	CbGeAlD
Sorafenib—RAF1—lung—lung cancer	0.000105	0.00375	CbGeAlD
Sorafenib—EPHB6—lung—lung cancer	0.000105	0.00373	CbGeAlD
Sorafenib—EPHX2—lymph node—lung cancer	0.000103	0.00368	CbGeAlD
Sorafenib—CYP3A4—Doxorubicin—lung cancer	0.000103	0.000343	CbGbCtD
Sorafenib—FLT3—lymph node—lung cancer	0.000103	0.00365	CbGeAlD
Sorafenib—PDGFRB—cardiac atrium—lung cancer	0.000101	0.00361	CbGeAlD
Sorafenib—STK10—lung—lung cancer	0.0001	0.00357	CbGeAlD
Sorafenib—PDGFRA—lung—lung cancer	9.93e-05	0.00354	CbGeAlD
Sorafenib—KDR—bone marrow—lung cancer	9.89e-05	0.00352	CbGeAlD
Sorafenib—CSF1R—bone marrow—lung cancer	9.65e-05	0.00344	CbGeAlD
Sorafenib—ABCC4—bronchus—lung cancer	9.57e-05	0.00341	CbGeAlD
Sorafenib—FLT4—lymph node—lung cancer	9.32e-05	0.00332	CbGeAlD
Sorafenib—FGFR1—lymph node—lung cancer	9.2e-05	0.00327	CbGeAlD
Sorafenib—KDR—lung—lung cancer	8.96e-05	0.00319	CbGeAlD
Sorafenib—MAP2K5—lung—lung cancer	8.96e-05	0.00319	CbGeAlD
Sorafenib—Vismodegib—ABCG2—lung cancer	8.86e-05	0.0394	CrCbGaD
Sorafenib—KIT—bone marrow—lung cancer	8.77e-05	0.00312	CbGeAlD
Sorafenib—CSF1R—lung—lung cancer	8.75e-05	0.00311	CbGeAlD
Sorafenib—MAP3K7—lymph node—lung cancer	8.71e-05	0.0031	CbGeAlD
Sorafenib—PDGFRB—bone marrow—lung cancer	8.56e-05	0.00305	CbGeAlD
Sorafenib—MKNK2—lymph node—lung cancer	8.44e-05	0.003	CbGeAlD
Sorafenib—MKNK1—lymph node—lung cancer	8.33e-05	0.00297	CbGeAlD
Sorafenib—RET—lymph node—lung cancer	8.23e-05	0.00293	CbGeAlD
Sorafenib—KIT—lung—lung cancer	7.94e-05	0.00283	CbGeAlD
Sorafenib—CYP1A2—respiratory system—lung cancer	7.9e-05	0.00281	CbGeAlD
Sorafenib—PDGFRB—lung—lung cancer	7.76e-05	0.00276	CbGeAlD
Sorafenib—CDK7—Epirubicin—Doxorubicin—lung cancer	7.64e-05	0.0732	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Doxorubicin—lung cancer	7.64e-05	0.0732	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—lung cancer	7.64e-05	0.0732	CbGdCrCtD
Sorafenib—RALBP1—lymph node—lung cancer	7.62e-05	0.00271	CbGeAlD
Sorafenib—CYP3A5—respiratory system—lung cancer	7.62e-05	0.00271	CbGeAlD
Sorafenib—CYP2B6—respiratory system—lung cancer	7.57e-05	0.0027	CbGeAlD
Sorafenib—FLT1—lymph node—lung cancer	7.25e-05	0.00258	CbGeAlD
Sorafenib—RAF1—lymph node—lung cancer	7.21e-05	0.00257	CbGeAlD
Sorafenib—EPHB6—lymph node—lung cancer	7.17e-05	0.00255	CbGeAlD
Sorafenib—STK10—lymph node—lung cancer	6.86e-05	0.00244	CbGeAlD
Sorafenib—ABCC4—bone marrow—lung cancer	6.82e-05	0.00243	CbGeAlD
Sorafenib—PDGFRA—lymph node—lung cancer	6.79e-05	0.00242	CbGeAlD
Sorafenib—CYP2B6—bronchus—lung cancer	6.23e-05	0.00222	CbGeAlD
Sorafenib—ABCC4—lung—lung cancer	6.18e-05	0.0022	CbGeAlD
Sorafenib—HTR2B—lung—lung cancer	6.14e-05	0.00219	CbGeAlD
Sorafenib—MAP2K5—lymph node—lung cancer	6.13e-05	0.00218	CbGeAlD
Sorafenib—KDR—lymph node—lung cancer	6.13e-05	0.00218	CbGeAlD
Sorafenib—CSF1R—lymph node—lung cancer	5.98e-05	0.00213	CbGeAlD
Sorafenib—KIT—lymph node—lung cancer	5.43e-05	0.00193	CbGeAlD
Sorafenib—PDGFRB—lymph node—lung cancer	5.3e-05	0.00189	CbGeAlD
Sorafenib—ABCG2—bone marrow—lung cancer	4.81e-05	0.00171	CbGeAlD
Sorafenib—Regorafenib—ABCB1—lung cancer	4.65e-05	0.0207	CrCbGaD
Sorafenib—ABCG2—lung—lung cancer	4.36e-05	0.00155	CbGeAlD
Sorafenib—ABCC4—lymph node—lung cancer	4.22e-05	0.0015	CbGeAlD
Sorafenib—HTR2B—lymph node—lung cancer	4.2e-05	0.0015	CbGeAlD
Sorafenib—CYP1A2—lung—lung cancer	4.2e-05	0.00149	CbGeAlD
Sorafenib—ABCC2—lymph node—lung cancer	4.09e-05	0.00146	CbGeAlD
Sorafenib—ABCB1—respiratory system—lung cancer	4.05e-05	0.00144	CbGeAlD
Sorafenib—CYP3A5—lung—lung cancer	4.05e-05	0.00144	CbGeAlD
Sorafenib—CYP2B6—lung—lung cancer	4.02e-05	0.00143	CbGeAlD
Sorafenib—Vismodegib—ALB—lung cancer	3.87e-05	0.0172	CrCbGaD
Sorafenib—Vismodegib—ABCB1—lung cancer	3.69e-05	0.0164	CrCbGaD
Sorafenib—ABCB1—epithelium—lung cancer	3.38e-05	0.0012	CbGeAlD
Sorafenib—ABCB1—trachea—lung cancer	2.99e-05	0.00106	CbGeAlD
Sorafenib—ABCG2—lymph node—lung cancer	2.98e-05	0.00106	CbGeAlD
Sorafenib—ABCB1—bone marrow—lung cancer	2.37e-05	0.000845	CbGeAlD
Sorafenib—ABCB1—lung—lung cancer	2.15e-05	0.000765	CbGeAlD
Sorafenib—Abdominal pain—Irinotecan—lung cancer	1.67e-05	0.000263	CcSEcCtD
Sorafenib—Body temperature increased—Irinotecan—lung cancer	1.67e-05	0.000263	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Doxorubicin—lung cancer	1.67e-05	0.000263	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Doxorubicin—lung cancer	1.67e-05	0.000263	CcSEcCtD
Sorafenib—Decreased appetite—Cisplatin—lung cancer	1.66e-05	0.000263	CcSEcCtD
Sorafenib—Pneumonia—Methotrexate—lung cancer	1.66e-05	0.000262	CcSEcCtD
Sorafenib—Nasopharyngitis—Doxorubicin—lung cancer	1.65e-05	0.000261	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Cisplatin—lung cancer	1.65e-05	0.000261	CcSEcCtD
Sorafenib—Anaemia—Docetaxel—lung cancer	1.65e-05	0.000261	CcSEcCtD
Sorafenib—Infestation NOS—Methotrexate—lung cancer	1.65e-05	0.00026	CcSEcCtD
Sorafenib—Infestation—Methotrexate—lung cancer	1.65e-05	0.00026	CcSEcCtD
Sorafenib—Anorexia—Paclitaxel—lung cancer	1.64e-05	0.000259	CcSEcCtD
Sorafenib—Gastritis—Doxorubicin—lung cancer	1.64e-05	0.000259	CcSEcCtD
Sorafenib—Pain—Cisplatin—lung cancer	1.64e-05	0.000259	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—lung cancer	1.63e-05	0.000258	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Doxorubicin—lung cancer	1.63e-05	0.000258	CcSEcCtD
Sorafenib—Vomiting—Vinorelbine—lung cancer	1.62e-05	0.000257	CcSEcCtD
Sorafenib—Body temperature increased—Gemcitabine—lung cancer	1.62e-05	0.000256	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—lung cancer	1.62e-05	0.000256	CcSEcCtD
Sorafenib—Rash—Vinorelbine—lung cancer	1.61e-05	0.000255	CcSEcCtD
Sorafenib—Dermatitis—Vinorelbine—lung cancer	1.61e-05	0.000254	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—lung cancer	1.6e-05	0.000254	CcSEcCtD
Sorafenib—Headache—Vinorelbine—lung cancer	1.6e-05	0.000253	CcSEcCtD
Sorafenib—Syncope—Docetaxel—lung cancer	1.6e-05	0.000253	CcSEcCtD
Sorafenib—Dysphagia—Doxorubicin—lung cancer	1.6e-05	0.000253	CcSEcCtD
Sorafenib—Leukopenia—Docetaxel—lung cancer	1.6e-05	0.000253	CcSEcCtD
Sorafenib—Loss of consciousness—Docetaxel—lung cancer	1.57e-05	0.000248	CcSEcCtD
Sorafenib—Pancreatitis—Doxorubicin—lung cancer	1.57e-05	0.000248	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Paclitaxel—lung cancer	1.57e-05	0.000247	CcSEcCtD
Sorafenib—Dyspnoea—Etoposide—lung cancer	1.56e-05	0.000247	CcSEcCtD
Sorafenib—Cough—Docetaxel—lung cancer	1.56e-05	0.000246	CcSEcCtD
Sorafenib—Hepatobiliary disease—Methotrexate—lung cancer	1.56e-05	0.000246	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—lung cancer	1.55e-05	0.000245	CcSEcCtD
Sorafenib—Hypersensitivity—Irinotecan—lung cancer	1.55e-05	0.000245	CcSEcCtD
Sorafenib—Hypertension—Docetaxel—lung cancer	1.54e-05	0.000244	CcSEcCtD
Sorafenib—Dyspnoea—Paclitaxel—lung cancer	1.53e-05	0.000242	CcSEcCtD
Sorafenib—Decreased appetite—Etoposide—lung cancer	1.52e-05	0.000241	CcSEcCtD
Sorafenib—Myalgia—Docetaxel—lung cancer	1.52e-05	0.00024	CcSEcCtD
Sorafenib—Arthralgia—Docetaxel—lung cancer	1.52e-05	0.00024	CcSEcCtD
Sorafenib—Nausea—Vinorelbine—lung cancer	1.52e-05	0.00024	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Etoposide—lung cancer	1.51e-05	0.000239	CcSEcCtD
Sorafenib—Dyspepsia—Paclitaxel—lung cancer	1.51e-05	0.000239	CcSEcCtD
Sorafenib—Body temperature increased—Cisplatin—lung cancer	1.51e-05	0.000239	CcSEcCtD
Sorafenib—Asthenia—Irinotecan—lung cancer	1.51e-05	0.000239	CcSEcCtD
Sorafenib—Fatigue—Etoposide—lung cancer	1.51e-05	0.000239	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	1.51e-05	0.000239	CcSEcCtD
Sorafenib—Constipation—Etoposide—lung cancer	1.5e-05	0.000237	CcSEcCtD
Sorafenib—Pain—Etoposide—lung cancer	1.5e-05	0.000237	CcSEcCtD
Sorafenib—Neutropenia—Doxorubicin—lung cancer	1.49e-05	0.000236	CcSEcCtD
Sorafenib—Decreased appetite—Paclitaxel—lung cancer	1.49e-05	0.000236	CcSEcCtD
Sorafenib—Dry mouth—Docetaxel—lung cancer	1.49e-05	0.000235	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—lung cancer	1.49e-05	0.000235	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Paclitaxel—lung cancer	1.48e-05	0.000234	CcSEcCtD
Sorafenib—Fatigue—Paclitaxel—lung cancer	1.48e-05	0.000234	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—lung cancer	1.48e-05	0.000234	CcSEcCtD
Sorafenib—Asthenia—Gemcitabine—lung cancer	1.47e-05	0.000233	CcSEcCtD
Sorafenib—ABCB1—lymph node—lung cancer	1.47e-05	0.000523	CbGeAlD
Sorafenib—Pain—Paclitaxel—lung cancer	1.47e-05	0.000232	CcSEcCtD
Sorafenib—Constipation—Paclitaxel—lung cancer	1.47e-05	0.000232	CcSEcCtD
Sorafenib—Urinary tract disorder—Methotrexate—lung cancer	1.46e-05	0.000231	CcSEcCtD
Sorafenib—Anaphylactic shock—Docetaxel—lung cancer	1.46e-05	0.00023	CcSEcCtD
Sorafenib—Pruritus—Gemcitabine—lung cancer	1.45e-05	0.00023	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—lung cancer	1.45e-05	0.000229	CcSEcCtD
Sorafenib—Infection—Docetaxel—lung cancer	1.45e-05	0.000229	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—lung cancer	1.45e-05	0.000229	CcSEcCtD
Sorafenib—Diarrhoea—Irinotecan—lung cancer	1.44e-05	0.000228	CcSEcCtD
Sorafenib—Pneumonia—Doxorubicin—lung cancer	1.43e-05	0.000227	CcSEcCtD
Sorafenib—Gastrointestinal pain—Etoposide—lung cancer	1.43e-05	0.000227	CcSEcCtD
Sorafenib—Shock—Docetaxel—lung cancer	1.43e-05	0.000227	CcSEcCtD
Sorafenib—Nervous system disorder—Docetaxel—lung cancer	1.43e-05	0.000226	CcSEcCtD
Sorafenib—Thrombocytopenia—Docetaxel—lung cancer	1.43e-05	0.000225	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—lung cancer	1.43e-05	0.000225	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—lung cancer	1.43e-05	0.000225	CcSEcCtD
Sorafenib—Skin disorder—Docetaxel—lung cancer	1.41e-05	0.000224	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—lung cancer	1.41e-05	0.000223	CcSEcCtD
Sorafenib—Hypersensitivity—Cisplatin—lung cancer	1.41e-05	0.000223	CcSEcCtD
Sorafenib—Gastrointestinal pain—Paclitaxel—lung cancer	1.41e-05	0.000222	CcSEcCtD
Sorafenib—Diarrhoea—Gemcitabine—lung cancer	1.4e-05	0.000222	CcSEcCtD
Sorafenib—Renal failure—Doxorubicin—lung cancer	1.4e-05	0.000221	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—lung cancer	1.4e-05	0.000221	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—lung cancer	1.4e-05	0.000221	CcSEcCtD
Sorafenib—Dizziness—Irinotecan—lung cancer	1.39e-05	0.00022	CcSEcCtD
Sorafenib—Urticaria—Etoposide—lung cancer	1.39e-05	0.00022	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—lung cancer	1.39e-05	0.00022	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—lung cancer	1.39e-05	0.00022	CcSEcCtD
Sorafenib—Anorexia—Docetaxel—lung cancer	1.39e-05	0.000219	CcSEcCtD
Sorafenib—Body temperature increased—Etoposide—lung cancer	1.39e-05	0.000219	CcSEcCtD
Sorafenib—Abdominal pain—Etoposide—lung cancer	1.39e-05	0.000219	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—lung cancer	1.38e-05	0.000218	CcSEcCtD
Sorafenib—Asthenia—Cisplatin—lung cancer	1.37e-05	0.000217	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—lung cancer	1.37e-05	0.000217	CcSEcCtD
Sorafenib—Urticaria—Paclitaxel—lung cancer	1.37e-05	0.000216	CcSEcCtD
Sorafenib—Abdominal pain—Paclitaxel—lung cancer	1.36e-05	0.000215	CcSEcCtD
Sorafenib—Body temperature increased—Paclitaxel—lung cancer	1.36e-05	0.000215	CcSEcCtD
Sorafenib—Hepatobiliary disease—Doxorubicin—lung cancer	1.35e-05	0.000213	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—lung cancer	1.34e-05	0.000212	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—lung cancer	1.34e-05	0.000212	CcSEcCtD
Sorafenib—Vomiting—Irinotecan—lung cancer	1.34e-05	0.000212	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—lung cancer	1.33e-05	0.000211	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—lung cancer	1.33e-05	0.00021	CcSEcCtD
Sorafenib—Rash—Irinotecan—lung cancer	1.33e-05	0.00021	CcSEcCtD
Sorafenib—Dermatitis—Irinotecan—lung cancer	1.33e-05	0.00021	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Docetaxel—lung cancer	1.33e-05	0.00021	CcSEcCtD
Sorafenib—Headache—Irinotecan—lung cancer	1.32e-05	0.000209	CcSEcCtD
Sorafenib—Diarrhoea—Cisplatin—lung cancer	1.31e-05	0.000207	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—lung cancer	1.31e-05	0.000206	CcSEcCtD
Sorafenib—Vomiting—Gemcitabine—lung cancer	1.31e-05	0.000206	CcSEcCtD
Sorafenib—Dyspnoea—Docetaxel—lung cancer	1.3e-05	0.000205	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—lung cancer	1.29e-05	0.000205	CcSEcCtD
Sorafenib—Rash—Gemcitabine—lung cancer	1.29e-05	0.000205	CcSEcCtD
Sorafenib—Dermatitis—Gemcitabine—lung cancer	1.29e-05	0.000204	CcSEcCtD
Sorafenib—Hypersensitivity—Etoposide—lung cancer	1.29e-05	0.000204	CcSEcCtD
Sorafenib—Erythema—Methotrexate—lung cancer	1.29e-05	0.000203	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—lung cancer	1.29e-05	0.000203	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—lung cancer	1.29e-05	0.000203	CcSEcCtD
Sorafenib—Headache—Gemcitabine—lung cancer	1.29e-05	0.000203	CcSEcCtD
Sorafenib—Dyspepsia—Docetaxel—lung cancer	1.28e-05	0.000203	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—lung cancer	1.28e-05	0.000202	CcSEcCtD
Sorafenib—Decreased appetite—Docetaxel—lung cancer	1.27e-05	0.0002	CcSEcCtD
Sorafenib—Hypersensitivity—Paclitaxel—lung cancer	1.27e-05	0.0002	CcSEcCtD
Sorafenib—Urinary tract disorder—Doxorubicin—lung cancer	1.26e-05	0.0002	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—lung cancer	1.26e-05	0.000199	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Docetaxel—lung cancer	1.26e-05	0.000199	CcSEcCtD
Sorafenib—Asthenia—Etoposide—lung cancer	1.26e-05	0.000199	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—lung cancer	1.26e-05	0.000199	CcSEcCtD
Sorafenib—Fatigue—Docetaxel—lung cancer	1.26e-05	0.000198	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—lung cancer	1.25e-05	0.000198	CcSEcCtD
Sorafenib—Nausea—Irinotecan—lung cancer	1.25e-05	0.000198	CcSEcCtD
Sorafenib—Pain—Docetaxel—lung cancer	1.25e-05	0.000197	CcSEcCtD
Sorafenib—Constipation—Docetaxel—lung cancer	1.25e-05	0.000197	CcSEcCtD
Sorafenib—Pruritus—Etoposide—lung cancer	1.24e-05	0.000196	CcSEcCtD
Sorafenib—Asthenia—Paclitaxel—lung cancer	1.23e-05	0.000195	CcSEcCtD
Sorafenib—Nausea—Gemcitabine—lung cancer	1.22e-05	0.000193	CcSEcCtD
Sorafenib—Vomiting—Cisplatin—lung cancer	1.22e-05	0.000192	CcSEcCtD
Sorafenib—Pruritus—Paclitaxel—lung cancer	1.22e-05	0.000192	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—lung cancer	1.21e-05	0.000191	CcSEcCtD
Sorafenib—Rash—Cisplatin—lung cancer	1.21e-05	0.000191	CcSEcCtD
Sorafenib—Dermatitis—Cisplatin—lung cancer	1.21e-05	0.00019	CcSEcCtD
Sorafenib—Diarrhoea—Etoposide—lung cancer	1.2e-05	0.00019	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—lung cancer	1.19e-05	0.000189	CcSEcCtD
Sorafenib—Gastrointestinal pain—Docetaxel—lung cancer	1.19e-05	0.000188	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—lung cancer	1.19e-05	0.000188	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—lung cancer	1.19e-05	0.000188	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—lung cancer	1.19e-05	0.000188	CcSEcCtD
Sorafenib—Diarrhoea—Paclitaxel—lung cancer	1.18e-05	0.000186	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—lung cancer	1.16e-05	0.000183	CcSEcCtD
Sorafenib—Dizziness—Etoposide—lung cancer	1.16e-05	0.000183	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—lung cancer	1.16e-05	0.000183	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—lung cancer	1.15e-05	0.000182	CcSEcCtD
Sorafenib—Body temperature increased—Docetaxel—lung cancer	1.15e-05	0.000182	CcSEcCtD
Sorafenib—Abdominal pain—Docetaxel—lung cancer	1.15e-05	0.000182	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—lung cancer	1.15e-05	0.000182	CcSEcCtD
Sorafenib—Arrhythmia—Doxorubicin—lung cancer	1.14e-05	0.000181	CcSEcCtD
Sorafenib—Dizziness—Paclitaxel—lung cancer	1.14e-05	0.00018	CcSEcCtD
Sorafenib—Nausea—Cisplatin—lung cancer	1.14e-05	0.00018	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—lung cancer	1.13e-05	0.000179	CcSEcCtD
Sorafenib—Cough—Methotrexate—lung cancer	1.12e-05	0.000177	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—lung cancer	1.12e-05	0.000177	CcSEcCtD
Sorafenib—Vomiting—Etoposide—lung cancer	1.11e-05	0.000176	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—lung cancer	1.11e-05	0.000176	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—lung cancer	1.11e-05	0.000176	CcSEcCtD
Sorafenib—Rash—Etoposide—lung cancer	1.11e-05	0.000175	CcSEcCtD
Sorafenib—Dermatitis—Etoposide—lung cancer	1.1e-05	0.000175	CcSEcCtD
Sorafenib—Headache—Etoposide—lung cancer	1.1e-05	0.000174	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—lung cancer	1.1e-05	0.000173	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—lung cancer	1.1e-05	0.000173	CcSEcCtD
Sorafenib—Vomiting—Paclitaxel—lung cancer	1.09e-05	0.000173	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—lung cancer	1.09e-05	0.000172	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	1.09e-05	0.000172	CcSEcCtD
Sorafenib—Rash—Paclitaxel—lung cancer	1.08e-05	0.000171	CcSEcCtD
Sorafenib—Dermatitis—Paclitaxel—lung cancer	1.08e-05	0.000171	CcSEcCtD
Sorafenib—Headache—Paclitaxel—lung cancer	1.08e-05	0.00017	CcSEcCtD
Sorafenib—Hypersensitivity—Docetaxel—lung cancer	1.07e-05	0.00017	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—lung cancer	1.07e-05	0.000169	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—lung cancer	1.05e-05	0.000166	CcSEcCtD
Sorafenib—Asthenia—Docetaxel—lung cancer	1.05e-05	0.000165	CcSEcCtD
Sorafenib—Infection—Methotrexate—lung cancer	1.04e-05	0.000165	CcSEcCtD
Sorafenib—Nausea—Etoposide—lung cancer	1.04e-05	0.000165	CcSEcCtD
Sorafenib—Pruritus—Docetaxel—lung cancer	1.03e-05	0.000163	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—lung cancer	1.03e-05	0.000163	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—lung cancer	1.03e-05	0.000163	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—lung cancer	1.03e-05	0.000162	CcSEcCtD
Sorafenib—Nausea—Paclitaxel—lung cancer	1.02e-05	0.000161	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—lung cancer	1.02e-05	0.000161	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—lung cancer	1e-05	0.000158	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—lung cancer	9.99e-06	0.000158	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—lung cancer	9.97e-06	0.000158	CcSEcCtD
Sorafenib—Diarrhoea—Docetaxel—lung cancer	9.97e-06	0.000158	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—lung cancer	9.79e-06	0.000155	CcSEcCtD
Sorafenib—Cough—Doxorubicin—lung cancer	9.72e-06	0.000154	CcSEcCtD
Sorafenib—Dizziness—Docetaxel—lung cancer	9.63e-06	0.000152	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—lung cancer	9.62e-06	0.000152	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methotrexate—lung cancer	9.57e-06	0.000151	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—lung cancer	9.48e-06	0.00015	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—lung cancer	9.48e-06	0.00015	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	9.42e-06	0.000149	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—lung cancer	9.36e-06	0.000148	CcSEcCtD
Sorafenib—Dry mouth—Doxorubicin—lung cancer	9.28e-06	0.000147	CcSEcCtD
Sorafenib—Vomiting—Docetaxel—lung cancer	9.26e-06	0.000146	CcSEcCtD
Sorafenib—Dyspepsia—Methotrexate—lung cancer	9.24e-06	0.000146	CcSEcCtD
Sorafenib—Rash—Docetaxel—lung cancer	9.19e-06	0.000145	CcSEcCtD
Sorafenib—Dermatitis—Docetaxel—lung cancer	9.18e-06	0.000145	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—lung cancer	9.13e-06	0.000144	CcSEcCtD
Sorafenib—Headache—Docetaxel—lung cancer	9.13e-06	0.000144	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—lung cancer	9.09e-06	0.000144	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—lung cancer	9.06e-06	0.000143	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—lung cancer	9.05e-06	0.000143	CcSEcCtD
Sorafenib—Infection—Doxorubicin—lung cancer	9.03e-06	0.000143	CcSEcCtD
Sorafenib—Pain—Methotrexate—lung cancer	8.98e-06	0.000142	CcSEcCtD
Sorafenib—Shock—Doxorubicin—lung cancer	8.94e-06	0.000141	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—lung cancer	8.92e-06	0.000141	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—lung cancer	8.9e-06	0.000141	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—lung cancer	8.83e-06	0.00014	CcSEcCtD
Sorafenib—Anorexia—Doxorubicin—lung cancer	8.67e-06	0.000137	CcSEcCtD
Sorafenib—Nausea—Docetaxel—lung cancer	8.65e-06	0.000137	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—lung cancer	8.59e-06	0.000136	CcSEcCtD
Sorafenib—Urticaria—Methotrexate—lung cancer	8.34e-06	0.000132	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—lung cancer	8.3e-06	0.000131	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—lung cancer	8.3e-06	0.000131	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—lung cancer	8.28e-06	0.000131	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—lung cancer	8.11e-06	0.000128	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—lung cancer	8e-06	0.000126	CcSEcCtD
Sorafenib—Decreased appetite—Doxorubicin—lung cancer	7.9e-06	0.000125	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—lung cancer	7.85e-06	0.000124	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—lung cancer	7.84e-06	0.000124	CcSEcCtD
Sorafenib—Pain—Doxorubicin—lung cancer	7.77e-06	0.000123	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—lung cancer	7.77e-06	0.000123	CcSEcCtD
Sorafenib—Hypersensitivity—Methotrexate—lung cancer	7.74e-06	0.000122	CcSEcCtD
Sorafenib—Asthenia—Methotrexate—lung cancer	7.53e-06	0.000119	CcSEcCtD
Sorafenib—Gastrointestinal pain—Doxorubicin—lung cancer	7.43e-06	0.000117	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—lung cancer	7.43e-06	0.000117	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—lung cancer	7.22e-06	0.000114	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—lung cancer	7.19e-06	0.000114	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—lung cancer	7.19e-06	0.000114	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—lung cancer	7.18e-06	0.000114	CcSEcCtD
Sorafenib—Dizziness—Methotrexate—lung cancer	6.94e-06	0.00011	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—lung cancer	6.7e-06	0.000106	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—lung cancer	6.68e-06	0.000106	CcSEcCtD
Sorafenib—Rash—Methotrexate—lung cancer	6.62e-06	0.000105	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—lung cancer	6.61e-06	0.000105	CcSEcCtD
Sorafenib—Headache—Methotrexate—lung cancer	6.58e-06	0.000104	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—lung cancer	6.52e-06	0.000103	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—lung cancer	6.43e-06	0.000102	CcSEcCtD
Sorafenib—Nausea—Methotrexate—lung cancer	6.24e-06	9.86e-05	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—lung cancer	6.22e-06	9.83e-05	CcSEcCtD
Sorafenib—Dizziness—Doxorubicin—lung cancer	6.01e-06	9.5e-05	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—lung cancer	5.78e-06	9.14e-05	CcSEcCtD
Sorafenib—Rash—Doxorubicin—lung cancer	5.73e-06	9.06e-05	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—lung cancer	5.73e-06	9.05e-05	CcSEcCtD
Sorafenib—Headache—Doxorubicin—lung cancer	5.7e-06	9e-05	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—lung cancer	5.4e-06	8.53e-05	CcSEcCtD
Sorafenib—CYP2B6—Metabolism—PIK3CD—lung cancer	2.59e-07	4.19e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—lung cancer	2.59e-07	4.19e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—lung cancer	2.58e-07	4.18e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—lung cancer	2.58e-07	4.17e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB2—lung cancer	2.58e-07	4.17e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.58e-07	4.17e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—lung cancer	2.57e-07	4.17e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—lung cancer	2.57e-07	4.17e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—lung cancer	2.57e-07	4.16e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ERCC2—lung cancer	2.57e-07	4.15e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—lung cancer	2.57e-07	4.15e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—lung cancer	2.56e-07	4.15e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—lung cancer	2.56e-07	4.14e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—lung cancer	2.56e-07	4.14e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1A—lung cancer	2.55e-07	4.13e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—lung cancer	2.55e-07	4.13e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NRAS—lung cancer	2.55e-07	4.13e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—lung cancer	2.55e-07	4.13e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—lung cancer	2.55e-07	4.12e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTEN—lung cancer	2.55e-07	4.12e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CB—lung cancer	2.55e-07	4.12e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MTOR—lung cancer	2.55e-07	4.12e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTP1—lung cancer	2.54e-07	4.11e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—lung cancer	2.54e-07	4.11e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—EP300—lung cancer	2.54e-07	4.1e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CD—lung cancer	2.53e-07	4.09e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SRC—lung cancer	2.53e-07	4.09e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—lung cancer	2.51e-07	4.07e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—EP300—lung cancer	2.51e-07	4.07e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—lung cancer	2.5e-07	4.04e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—lung cancer	2.49e-07	4.03e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CG—lung cancer	2.49e-07	4.03e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—lung cancer	2.49e-07	4.02e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAT—lung cancer	2.47e-07	4e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—lung cancer	2.46e-07	3.99e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—lung cancer	2.46e-07	3.98e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.46e-07	3.98e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—lung cancer	2.45e-07	3.96e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—lung cancer	2.44e-07	3.95e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK3—lung cancer	2.44e-07	3.95e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—lung cancer	2.44e-07	3.95e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—lung cancer	2.44e-07	3.94e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOA1—lung cancer	2.44e-07	3.94e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NRAS—lung cancer	2.43e-07	3.94e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—lung cancer	2.43e-07	3.93e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EP300—lung cancer	2.43e-07	3.93e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—lung cancer	2.43e-07	3.93e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—lung cancer	2.4e-07	3.89e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCB1—lung cancer	2.4e-07	3.89e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOA1—lung cancer	2.38e-07	3.85e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2E1—lung cancer	2.38e-07	3.85e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—lung cancer	2.38e-07	3.85e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—lung cancer	2.38e-07	3.84e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—POMC—lung cancer	2.37e-07	3.84e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—lung cancer	2.37e-07	3.83e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—lung cancer	2.37e-07	3.83e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SRC—lung cancer	2.36e-07	3.82e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—lung cancer	2.36e-07	3.82e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TYMS—lung cancer	2.36e-07	3.82e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—lung cancer	2.35e-07	3.81e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NQO1—lung cancer	2.35e-07	3.8e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—lung cancer	2.34e-07	3.79e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—lung cancer	2.34e-07	3.78e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTM1—lung cancer	2.33e-07	3.78e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.33e-07	3.77e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK3—lung cancer	2.33e-07	3.77e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—lung cancer	2.33e-07	3.76e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—lung cancer	2.32e-07	3.76e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—lung cancer	2.32e-07	3.76e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CREBBP—lung cancer	2.31e-07	3.74e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—lung cancer	2.3e-07	3.72e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—lung cancer	2.3e-07	3.72e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—lung cancer	2.29e-07	3.7e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—lung cancer	2.29e-07	3.7e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—lung cancer	2.28e-07	3.69e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—lung cancer	2.28e-07	3.69e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—JUN—lung cancer	2.27e-07	3.68e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NRAS—lung cancer	2.27e-07	3.68e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—lung cancer	2.27e-07	3.68e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—lung cancer	2.27e-07	3.68e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—lung cancer	2.27e-07	3.67e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CB—lung cancer	2.26e-07	3.65e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—lung cancer	2.25e-07	3.63e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOA1—lung cancer	2.24e-07	3.63e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—lung cancer	2.24e-07	3.62e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—lung cancer	2.23e-07	3.62e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CG—lung cancer	2.22e-07	3.6e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOA1—lung cancer	2.22e-07	3.59e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—lung cancer	2.22e-07	3.59e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—lung cancer	2.21e-07	3.58e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP1A1—lung cancer	2.21e-07	3.58e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—lung cancer	2.21e-07	3.58e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—lung cancer	2.21e-07	3.58e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1A—lung cancer	2.21e-07	3.57e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CB—lung cancer	2.2e-07	3.57e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTEN—lung cancer	2.2e-07	3.56e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—lung cancer	2.2e-07	3.55e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ERCC2—lung cancer	2.19e-07	3.55e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CD—lung cancer	2.19e-07	3.54e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—lung cancer	2.19e-07	3.54e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—lung cancer	2.19e-07	3.54e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—lung cancer	2.18e-07	3.53e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK3—lung cancer	2.18e-07	3.52e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—lung cancer	2.17e-07	3.51e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CG—lung cancer	2.17e-07	3.51e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—lung cancer	2.17e-07	3.51e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—lung cancer	2.16e-07	3.5e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—lung cancer	2.15e-07	3.47e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—lung cancer	2.14e-07	3.47e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.13e-07	3.44e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—lung cancer	2.12e-07	3.44e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—STK11—lung cancer	2.12e-07	3.43e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—lung cancer	2.12e-07	3.43e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—POMC—lung cancer	2.12e-07	3.43e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EP300—lung cancer	2.1e-07	3.39e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—lung cancer	2.1e-07	3.39e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—lung cancer	2.09e-07	3.39e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—lung cancer	2.09e-07	3.39e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—lung cancer	2.09e-07	3.39e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—lung cancer	2.08e-07	3.36e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—lung cancer	2.07e-07	3.35e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—lung cancer	2.07e-07	3.35e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—POMC—lung cancer	2.07e-07	3.34e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CREBBP—lung cancer	2.06e-07	3.34e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CG—lung cancer	2.05e-07	3.31e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SRC—lung cancer	2.04e-07	3.3e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CG—lung cancer	2.03e-07	3.28e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—lung cancer	2.02e-07	3.26e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CREBBP—lung cancer	2.01e-07	3.26e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—lung cancer	1.99e-07	3.22e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—lung cancer	1.99e-07	3.22e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—lung cancer	1.98e-07	3.21e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—lung cancer	1.97e-07	3.18e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRAS—lung cancer	1.96e-07	3.18e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTP1—lung cancer	1.96e-07	3.17e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—lung cancer	1.96e-07	3.17e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CD—lung cancer	1.96e-07	3.16e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—lung cancer	1.95e-07	3.16e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTEN—lung cancer	1.95e-07	3.15e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—POMC—lung cancer	1.95e-07	3.15e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—lung cancer	1.93e-07	3.13e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—lung cancer	1.93e-07	3.13e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—POMC—lung cancer	1.93e-07	3.12e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—lung cancer	1.93e-07	3.12e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—lung cancer	1.92e-07	3.11e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CB—lung cancer	1.91e-07	3.09e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CD—lung cancer	1.91e-07	3.09e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAT—lung cancer	1.91e-07	3.09e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTEN—lung cancer	1.9e-07	3.08e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOA1—lung cancer	1.9e-07	3.07e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CREBBP—lung cancer	1.9e-07	3.07e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—lung cancer	1.89e-07	3.06e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—lung cancer	1.88e-07	3.05e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CREBBP—lung cancer	1.88e-07	3.04e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK3—lung cancer	1.88e-07	3.04e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—lung cancer	1.88e-07	3.03e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—lung cancer	1.87e-07	3.02e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—lung cancer	1.86e-07	3.01e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—lung cancer	1.86e-07	3.01e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—EP300—lung cancer	1.86e-07	3.01e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCB1—lung cancer	1.86e-07	3e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—lung cancer	1.83e-07	2.97e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—lung cancer	1.83e-07	2.96e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—lung cancer	1.83e-07	2.96e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TYMS—lung cancer	1.82e-07	2.95e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.82e-07	2.94e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—EP300—lung cancer	1.82e-07	2.94e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—lung cancer	1.81e-07	2.92e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—lung cancer	1.81e-07	2.92e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTM1—lung cancer	1.8e-07	2.91e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CD—lung cancer	1.8e-07	2.91e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—lung cancer	1.8e-07	2.91e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—lung cancer	1.79e-07	2.89e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—lung cancer	1.79e-07	2.89e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CD—lung cancer	1.78e-07	2.88e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—lung cancer	1.78e-07	2.88e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—lung cancer	1.78e-07	2.87e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—lung cancer	1.76e-07	2.85e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—lung cancer	1.74e-07	2.81e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CG—lung cancer	1.73e-07	2.8e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1A1—lung cancer	1.71e-07	2.76e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CB—lung cancer	1.7e-07	2.76e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—lung cancer	1.7e-07	2.76e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ERCC2—lung cancer	1.69e-07	2.74e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—lung cancer	1.69e-07	2.73e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—lung cancer	1.69e-07	2.73e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—lung cancer	1.66e-07	2.69e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CB—lung cancer	1.66e-07	2.69e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTEN—lung cancer	1.65e-07	2.67e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—POMC—lung cancer	1.65e-07	2.67e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—lung cancer	1.65e-07	2.67e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—lung cancer	1.65e-07	2.67e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CREBBP—lung cancer	1.61e-07	2.6e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—lung cancer	1.59e-07	2.58e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—EP300—lung cancer	1.57e-07	2.55e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—lung cancer	1.57e-07	2.54e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CB—lung cancer	1.57e-07	2.54e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CB—lung cancer	1.55e-07	2.51e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—lung cancer	1.55e-07	2.51e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—lung cancer	1.55e-07	2.51e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—lung cancer	1.54e-07	2.49e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—lung cancer	1.53e-07	2.48e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CD—lung cancer	1.52e-07	2.47e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—lung cancer	1.52e-07	2.46e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—lung cancer	1.5e-07	2.43e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—lung cancer	1.5e-07	2.43e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTEN—lung cancer	1.47e-07	2.38e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—lung cancer	1.47e-07	2.38e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOA1—lung cancer	1.47e-07	2.37e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTEN—lung cancer	1.44e-07	2.33e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—lung cancer	1.44e-07	2.32e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—EP300—lung cancer	1.4e-07	2.27e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—lung cancer	1.37e-07	2.22e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—lung cancer	1.37e-07	2.22e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—EP300—lung cancer	1.37e-07	2.22e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTEN—lung cancer	1.35e-07	2.19e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—lung cancer	1.34e-07	2.17e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTEN—lung cancer	1.34e-07	2.17e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CG—lung cancer	1.34e-07	2.16e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CB—lung cancer	1.33e-07	2.15e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—lung cancer	1.32e-07	2.13e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—EP300—lung cancer	1.29e-07	2.09e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—EP300—lung cancer	1.28e-07	2.07e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—POMC—lung cancer	1.27e-07	2.06e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—lung cancer	1.27e-07	2.05e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CREBBP—lung cancer	1.24e-07	2.01e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CD—lung cancer	1.18e-07	1.9e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—lung cancer	1.16e-07	1.88e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—lung cancer	1.16e-07	1.88e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTEN—lung cancer	1.15e-07	1.86e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—lung cancer	1.12e-07	1.82e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—lung cancer	1.1e-07	1.78e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—EP300—lung cancer	1.09e-07	1.77e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—lung cancer	1.04e-07	1.68e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CB—lung cancer	1.02e-07	1.66e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—lung cancer	1.02e-07	1.64e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—lung cancer	1.01e-07	1.64e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—lung cancer	9.56e-08	1.55e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—lung cancer	9.51e-08	1.54e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—lung cancer	9.47e-08	1.53e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTEN—lung cancer	8.86e-08	1.43e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—lung cancer	8.49e-08	1.37e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—EP300—lung cancer	8.45e-08	1.37e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—lung cancer	8.28e-08	1.34e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—lung cancer	8.1e-08	1.31e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—lung cancer	7.81e-08	1.26e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—lung cancer	7.74e-08	1.25e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—lung cancer	6.61e-08	1.07e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—lung cancer	6.25e-08	1.01e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—lung cancer	5.1e-08	8.26e-07	CbGpPWpGaD
